Kinetics of mycolactone in human subcutaneous tissue during antibiotic therapy for Mycobacterium ulcerans disease

[1]  O. Stojadinović,et al.  Clinical application of growth factors and cytokines in wound healing , 2014, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[2]  Y. Amoako,et al.  Clinical and Bacteriological Efficacy of Rifampin-Streptomycin Combination for Two Weeks followed by Rifampin and Clarithromycin for Six Weeks for Treatment of Mycobacterium ulcerans Disease , 2014, Antimicrobial Agents and Chemotherapy.

[3]  Marie-France Carlier,et al.  Mycolactone activation of Wiskott-Aldrich syndrome proteins underpins Buruli ulcer formation. , 2013, The Journal of clinical investigation.

[4]  C. Robinson,et al.  Microbiological, Histological, Immunological, and Toxin Response to Antibiotic Treatment in the Mouse Model of Mycobacterium ulcerans Disease , 2013, PLoS neglected tropical diseases.

[5]  Y. Amoako,et al.  Detection of Viable Mycobacterium ulcerans in Clinical Samples by a Novel Combined 16S rRNA Reverse Transcriptase/IS2404 Real-Time qPCR Assay , 2012, PLoS neglected tropical diseases.

[6]  Georges Bismuth,et al.  Mycolactone impairs T cell homing by suppressing microRNA control of L-selectin expression , 2011, Proceedings of the National Academy of Sciences.

[7]  Enrico Colombo,et al.  A Mycobacterium ulcerans toxin, mycolactone, induces apoptosis in primary human keratinocytes and in HaCaT cells. , 2010, Microbes and infection.

[8]  M. Ståhle,et al.  Antioxidants Protect Keratinocytes against M. ulcerans Mycolactone Cytotoxicity , 2010, PloS one.

[9]  F. Sarfo,et al.  Clinical Efficacy of Combination of Rifampin and Streptomycin for Treatment of Mycobacterium ulcerans Disease , 2010, Antimicrobial Agents and Chemotherapy.

[10]  G. Bretzel,et al.  Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial , 2010, The Lancet.

[11]  F. Sarfo,et al.  Detection of Mycolactone A/B in Mycobacterium ulcerans–Infected Human Tissue , 2010, PLoS neglected tropical diseases.

[12]  B. Foxwell,et al.  Mycolactone Inhibits Monocyte Cytokine Production by a Posttranscriptional Mechanism1 , 2009, The Journal of Immunology.

[13]  F. Sarfo,et al.  Sensitivity of PCR Targeting Mycobacterium ulcerans by Use of Fine-Needle Aspirates for Diagnosis of Buruli Ulcer , 2009, Journal of Clinical Microbiology.

[14]  Olivera Stojadinovic,et al.  PERSPECTIVE ARTICLE: Growth factors and cytokines in wound healing , 2008, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[15]  Hui Hong,et al.  Mycolactones: immunosuppressive and cytotoxic polyketides produced by aquatic mycobacteria , 2008, Natural product reports.

[16]  Angelo Martino,et al.  Selective suppression of dendritic cell functions by Mycobacterium ulcerans toxin mycolactone , 2007, The Journal of experimental medicine.

[17]  Sarojini Adusumilli,et al.  Mycolactone-Mediated Inhibition of Tumor Necrosis Factor Production by Macrophages Infected with Mycobacterium ulcerans Has Implications for the Control of Infection , 2007, Infection and Immunity.

[18]  Pierre Legras,et al.  Impact of Mycobacterium ulcerans Biofilm on Transmissibility to Ecological Niches and Buruli Ulcer Pathogenesis , 2007, PLoS pathogens.

[19]  Sarojini Adusumilli,et al.  Mycobacterium ulcerans toxic macrolide, mycolactone modulates the host immune response and cellular location of M. ulcerans in vitro and in vivo , 2005, Cellular microbiology.

[20]  C. Horsfield,et al.  Efficacy of the Combination Rifampin-Streptomycin in Preventing Growth of Mycobacterium ulcerans in Early Lesions of Buruli Ulcer in Humans , 2005, Antimicrobial Agents and Chemotherapy.

[21]  Emmanuelle Perret,et al.  Modulation of the host immune response by a transient intracellular stage of Mycobacterium ulcerans: the contribution of endogenous mycolactone toxin , 2005, Cellular microbiology.

[22]  Sarojini Adusumilli,et al.  Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[23]  K. Dobos,et al.  Mycobacterium ulcerans Cytotoxicity in an Adipose Cell Model , 2001, Infection and Immunity.

[24]  B. Foxwell,et al.  The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. , 1999, Journal of immunology.

[25]  D. Chatterjee,et al.  Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. , 1999, Science.